Medical Professionals Online

NeoStem Announces Further Expansion In Northeastern U.S. With Strategic Alliance With New England Cryogenic Center, Inc.

July 16, 2017

NeoStem, Inc. (AMEX:NBS), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, has announced that the Company has entered into a strategic alliance with New England Cryogenic Center, Inc. (NECC), one of the largest cryogenic laboratories, to provide extensive processing and storing capacity as the Company continues to expand its services in the United States.

NECC, an FDA licensed and AABB accredited facility, will significantly increase NeoStem's ability to service its expanding Physician's Network that serves health-conscious clients interested in having their stem cells banked.

"Signing an agreement with a renowned partner such as NECC provides further validation for NeoStem's next generation stem cell services," said Mark Weinreb, President of NeoStem. "We believe this is a significant achievement in the Company's development as we prepare for what we believe will be a ramping up of demand by consumers to have their stem cells collected and stored on the East Coast to protect their future health."

NECC will be among the world's first facilities to offer the processing and storing of adult stem cells from healthy adults for their own future therapeutic use. NECC will leverage NeoStem's proprietary processes that allow patients to store their own stem cells for long periods of time to ensure prompt access in times of critical medical need. These cells are considered "autologous" as they are used by the donor exclusively for personal use to ensure biocompatibility.

"NeoStem continues to achieve strategic milestones during this very exciting period of expansion," said Robin Smith, M.D., Chief Executive Officer of NeoStem. "This new facility exemplifies our continued growth as it will provide ample capacity to store adult stem cells from what we expect to be an international customer base. NeoStem continues to execute on its first-to-market business strategy as a means to generate revenues and build shareholder value."

NeoStem's first-to-market competitive advantage uniquely positions the Company to capitalize on the hundreds of adult stem cell-based therapy clinical trials currently underway. As these stem cell-based therapies become available, NeoStem clients will be among the first to benefit from the life saving progress that is starting to be achieved in treating such debilitating conditions as cancer, heart disease, multiple sclerosis, lupus, and many others. These diseases currently affect more than 50 million Americans, a number that is expected to climb due to an aging population.

With collection centers already opened in California and Pennsylvania, NeoStem has begun processing and storing patients' stem cells, collected by skilled and experienced medical practitioners.

About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway at academic institutions and medical centers are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal "bio-insurance."

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at sec under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit CFSG1.

For more information, please visit: neostem.

For other information and resources about the Company, visit CFSG1
or trilogy-capital/tcp/neostem/quote.html.